SUZANO-VENTURES
24.4.2024 09:02:29 CEST | Business Wire | Press release
Suzano Ventures, the corporate venture capital arm of Suzano, the world’s largest market pulp producer, has made a strategic investment into the Canadian materials science startup, Bioform Technologies. The investment provides up to US$5 million towards the company’s seed round, enabling it to accelerate the development of its novel bio-based plastic alternatives. The products can be manufactured through modified industrial processes already used in the pulp and paper sector.
Bioform’s proprietary technology rapidly produces wood pulp-reinforced hydrogels to create high-performance plastic alternatives, which can be made using Suzano’s wood pulp fibre as a key input. Bioform’s materials have the potential to be home compostable or recycled through existing paper recycling processes and do not require fossil-based inputs. The technology is highly versatile and has a number of applications where it could replace conventional single-use plastics, including paper recyclable thermoformable films for packaging applications and compostable heat-sealable films for pouches, agriculture, and garbage bags.
With the potential to offer an 80 percent lower carbon footprint than conventional single-use plastics, Bioform’s technology has similar or enhanced product performance to conventional plastics in areas such as tensile strength and permeability for oxygen or water vapor.
Chris Clark, Chief Executive Officer of Bioform Technologies, said:
“Our goal is to produce sustainable alternatives to single-use plastics at the speed of paper and at the cost of plastic. We are harnessing the speed and efficiency of pulp and paper manufacturing to make swift and impactful steps into the marketplace. The technical validation and strategic investment from Suzano Ventures gives us a link to the world’s largest market pulp producer. We can also access Suzano’s world-leading expertise to help us rapidly accelerate the production efficiencies and cost reductions needed to make a significant reduction in the reliance on single-use plastics.”
Paula Puzzi, Senior Manager at Suzano Ventures, said:
“We’ve looked closely at Bioform’s technology and we see great promise in their technology and ability to disrupt the industry. Around the world, there are a number of innovations being developed that each offer more sustainable alternatives to the mountains of single-use plastic that we throw away each year, polluting our cities and soils, rivers, and seas. The great challenge is scaling production and getting to cost competitiveness versus cheap single-use plastic. By using renewable material and harnessing established industrial processes and machinery from the pulp and paper sector, we believe that Bioform has the opportunity to disrupt established supply chains and rapidly replace the need for fossil-based materials.”
Bioform has previously raised US$2.4 million from direct investments and US$1.2 million from non-dilutive sources to streamline its technology and validate performance and processes in its labs. This funding from Suzano Ventures will enable the company to realize a demonstration facility to pilot its manufacturing process and expand its team and capabilities.
Headquartered in São Paulo, Brazil, Suzano is the world’s largest market pulp producer and one of Latin America’s largest paper manufacturers. Producing its pulp entirely from farmed eucalyptus, the company’s products reach over 2 billion people around the world in over 100 countries. Suzano has had a presence in Canada since 2015, with a large research and development center for pulp, paper, and biomaterials technologies located in Vancouver.
About Suzano Ventures
Suzano Ventures is the venture capital arm of Suzano, the world’s largest market pulp producer - the key raw material for paper and packaging products that are part of the lives of more than 2 billion people around the world in over 100 countries. We invest globally in businesses that are pioneering innovative approaches to harness the power of trees, to help build the future of the bioeconomy.
We are committing an initial US$70 million to support the development and growth of companies across four investment areas: novel applications for eucalyptus biomaterials, sustainable packaging, forestry technology, and carbon removal. We help startups to grow, which in turn have the potential to develop and help shape the future of Suzano’s business.
Our strategic investments deliver shared value. By placing science at the heart of business, we help early-stage startups to grow, which, in turn, have the potential to develop and help shape the future of Suzano's business.
We provide our portfolio companies with capital, technical expertise, and market insights, alongside access to our global operations, supply chain and customer base. This includes the ability to engage with our hundreds of scientists, engineers, and technologists, based at Suzano’s research centers and operations across four continents.
About Bioform Technologies
Founded in 2021, Bioform has developed a proprietary method to manufacture plastic alternatives based on wood pulp reinforced hydrogels at high speeds by modifying existing pulp and paper making machinery. The manufacturing process has a low carbon footprint and can produce highly versatile materials to replace a wide range of single use plastics. Bioform has developed both compostable and paper-recyclable films that can be heat sealed or thermoformed depending on the application.
Bioform’s core technology was developed at the University of British Columbia by co-founders Jordan MacKenzie, the company’s current CTO, and Mark Martinez, Professor, Bio-Products Institute, University of British Columbia.
For further information please contact Chris Clark at cclark@bioformtech.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424575263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
